Galantamine : interactions médicamenteuses

Pyridostigmine bromide extended-release tablets are contraindicated in patients with: Mechanical intestinal or urinary obstruction Known hypersensitivity to pyridostigmine or other anticholinesterase agents Mechanical intestinal or urinary obstruction. (notice Pyridostigmine, Contre-indications)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (notice Galantamine, Mises en garde et précautions)

Cholinesterase inhibitors: Concomitant administration may increase the risk of cocaine toxicity. (notice Cocaïne, Interactions médicamenteuses)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Dicyclomine hydrochloride should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (5.4) (notice Dicyclovérine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. (notice Esmolol, Interactions médicamenteuses)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Use with caution due to aggravation of symptoms: Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), Parkinson’s disease ( 5.2 ), Myasthenia gravis ( 5.3 ), and Decreased gastrointestinal motility in patients with autonomic neuropathy ( 5.4 ). (notice Oxybutynine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

In case of simultaneous administration of other cholinesterase inhibitors (e.g. medicines for the treatment of dementia), caution should be exercised because of the potentiating effect. (notice Physostigmine, Interactions médicamenteuses)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Myasthenia Gravis Patients with myasthenia gravis may show worsening of symptoms from PA due to its procaine-like effect on diminishing acetylcholine release at skeletal muscle motor nerve endings, so that PA administration may be hazardous without optimal adjustment of anticholinesterase medications and other precautions. (notice Procaïnamide, Mises en garde)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

When Phase II block is suspected in cases of prolonged neuromuscular blockade, positive diagnosis should be made by peripheral nerve stimulation, prior to administration of any anticholinesterase drug. (notice Suxaméthonium, Mises en garde et précautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (notice Galantamine, Mises en garde et précautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (notice Galantamine, Mises en garde et précautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (notice Galantamine, Mises en garde et précautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Dexaméthasone, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. (notice Dipyridamole, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (notice Galantamine, Mises en garde et précautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (notice Galantamine, Interactions médicamenteuses)

Anticholinesterases : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Méthylprednisolone, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (notice Galantamine, Mises en garde et précautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisolone, Interactions médicamenteuses)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (notice Galantamine, Interactions médicamenteuses)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (notice Galantamine, Mises en garde et précautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (notice Galantamine, Mises en garde et précautions)

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Triamcinolone, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (notice Galantamine, Mises en garde et précautions)

In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (notice Rispéridone, Interactions médicamenteuses)